|Mol. mass||146.3 kDa (peptide)|
|(what is this?)|
Gantenerumab is currently being evaluated in a prodromal Alzheimer's disease population in the Scarlet Road study, a global phase II study of approximately 360 subjects in 100 centers in 15 countries. 
One clinical study was stopped on December 19, 2014 after disappointing results.
- Statement On A Nonproprietary Name Adopted By The Usan Council - Gantenerumab American Medical Association.
- International Nonproprietary Names for Pharmaceutical Substances (INN), World Health Organization.
- ClinicalTrials.gov NCT00531804 A Multiple Ascending Dose Study of R1450 in Patients With Alzheimer Disease
|This monoclonal antibody-related article is a stub. You can help Wikipedia by expanding it.|
|This drug article relating to the nervous system is a stub. You can help Wikipedia by expanding it.|